Dolutegravir moves nearer first filings as Shionogi bolsters R&D ahead of Crestor cliff
This article was originally published in Scrip
The first approval filings for the lead HIV integrase inhibitor dolutegravir (S/GSK-349572) being developed by the Shionogi-ViiV Healthcare joint venture are planned during the fiscal year ending 31 March 2013, the Japanese partner has said.
You may also be interested in...
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.